This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Stucki, A.
Right arrow Articles by Cottagnoud, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Stucki, A.
Right arrow Articles by Cottagnoud, P.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, February 2006, p. 770-773, Vol. 50, No. 2
0066-4804/06/$08.00+0     doi:10.1128/AAC.50.2.770-773.2006
Copyright © 2006, American Society for Microbiology. All Rights Reserved.

Efficacy of Telavancin against Penicillin-Resistant Pneumococci and Staphylococcus aureus in a Rabbit Meningitis Model and Determination of Kinetic Parameters

Armin Stucki,1 Peter Gerber,2 Fernando Acosta,3 Marianne Cottagnoud,3 and Philippe Cottagnoud1*

Department of Internal Medicine, Inselspital, Bern, Switzerland,1 Clinical of Pneumology, Inselspital, Bern, Switzerland,2 Clinical of Internal Medicine, Spital Bern-Ziegler, Bern, Switzerland3

Received 17 June 2005/ Returned for modification 1 August 2005/ Accepted 31 October 2005

The penetration of telavancin was 2% into inflamed meninges and ca. 1{per thousand} into noninflamed meninges after two intravenous injections (30 mg/kg of body weight). In experimental meningitis, telavancin was significantly superior to vancomycin combined with ceftriaxone against a penicillin-resistant pneumococcal strain. Against a methicillin-sensitive staphylococcal strain, telavancin was slightly but not significantly superior to vancomycin.

* Corresponding author. Mailing address: Department of Internal Medicine, Inselspital, Freiburgstrasse, 3010 Bern, Switzerland. Phone: 41-31-632-34-72. Fax: 41-31-632-38-47. E-mail: pcottagn{at}insel.ch.

Antimicrobial Agents and Chemotherapy, February 2006, p. 770-773, Vol. 50, No. 2
0066-4804/06/$08.00+0     doi:10.1128/AAC.50.2.770-773.2006
Copyright © 2006, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • LaPlante, K. L., Mermel, L. A. (2009). In Vitro Activities of Telavancin and Vancomycin against Biofilm-Producing Staphylococcus aureus, S. epidermidis, and Enterococcus faecalis Strains. Antimicrob. Agents Chemother. 53: 3166-3169 [Abstract] [Full Text]  
  • Charneski, L., Patel, P. N, Sym, D. (2009). Telavancin: A Novel Lipoglycopeptide Antibiotic. The Annals of Pharmacotherapy 43: 928-938 [Abstract] [Full Text]  
  • Attwood, R. J., LaPlante, K. L. (2007). Telavancin: A novel lipoglycopeptide antimicrobial agent. Am J Health Syst Pharm 64: 2335-2348 [Abstract] [Full Text]  
  • Miro, J. M., Garcia-de-la-Maria, C., Armero, Y., de-Lazzari, E., Soy, D., Moreno, A., del Rio, A., Almela, M., Mestres, C. A., Gatell, J. M., Jimenez-de-Anta, M.-T., Marco, F., and the Hospital Clinic Experimental Endocarditis, (2007). Efficacy of Telavancin in the Treatment of Experimental Endocarditis Due to Glycopeptide-Intermediate Staphylococcus aureus. Antimicrob. Agents Chemother. 51: 2373-2377 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»